Our People

Steven Lane

Associate Professor | Head of Cancer Program | Group Leader

Gordon and Jessie Gilmour Leukaemia Research Laboratory

+61 7 3362 0222

steven.lane@qimrberghofer.edu.au

 

CAREER HISTORY

Associate Professor Steven Lane is a clinical haematologist and devotes 30% of his time to seeing patients with leukaemia and related blood disorders at the Royal Brisbane and Women’s Hospital.  Associate Professor Lane is active in clinical trials including as principal investigator on prospective clinical trials in acute leukaemia and has accredited GCP training.

 

CURRENT APPOINTMENTS

  • Consultant Haematologist, Royal Brisbane and Women’s Hospital (RBWH)
  • Director of Clinical Research, Cancer Care Services, RBWH
  • Associate Professor, University of Queensland
  • Adjunct Associate Professor, Queensland University of Technology
  • Head, Cancer Theme, Brisbane Diamantina Health Partners
  • Member of National Blood Cancer Forum

 

PREVIOUS APPOINTMENTS

2011-2016: Team Head, Gordon and Jessie Gilmour Leukaemia Research Laboratory, QIMR Berghofer

2012-2014: Senior Lecturer, University of Queensland

2010-2011: Instructor in Paediatrics, Harvard Medical School, Children’s Hospital Boston

2008-2010: Postdoctoral Research Fellow, Harvard Medical School USA

2003-2008: Associate Lecturer, University of Queensland Medical School

2003-2008: Haematology Registrar, Queensland Health – RBWH and Princess Alexandra Hospital

1999-2001: Resident Medical Officer, Queensland Health – RBWH

 

ORCID NUMBER             

0000-0002-8050-6209

 

RESEARCHER ID               

C-3215-2012

 

CURRENT AREA OF RESEARCH

  • the laboratory researches myeloid blood cancers such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and the myeloproliferative neoplasms (MPN). These are very aggressive and rapidly fatal blood cancers that are among the most common types of cancer affecting Australians.  Our efforts are concentrated on understanding how leukaemia stem cells in AML and MPN are able to regenerate leukaemia (or cause relapse in patients), even after cytotoxic chemotherapy.  To achieve this, research has focused on generating robust models of leukaemia and dissecting the pathways of self-renewal in leukaemia stem cells and normal blood stem cells
  • Myeloproliferative neoplasms (MPN) – targeting disease-initiating stem cell populations through targeted inhibitors of Jak2 signaling or through inhibition of self-renewal pathways within stem cell populations
  • Acute myeloid leukaemia (AML) – examining the effect of inhibitors used alone, or in combination with chemotherapy on the preferential dependency of AML stem cells (compared to normal bone marrow) on pathways regulating DNA damage response and chromosomal stability. Identifying novel LSC-specific targets that may be of broader interest
  • normal blood development and pathways that regulate blood stem cell development

 

RESEARCH HIGHLIGHTS

  • targeting stem cells in myeloproliferative neoplasm
  • in vivo transformation of normal stem cells with Cdx2 leads to the development of MDS and AML
  • molecular screening and therapy in Leukaemia and Lymphoma (MoSTLLY) a translational clinical trials program to identify effective therapies for patients with blood cancer

 

PROFESSIONAL MEMBERSHIPS

2019

  • Treasurer & Queensland Councillor, Haematology Society of Australia and New Zealand

2013

  • European Hematology Association

2011

  • Australasian Leukaemia and Lymphoma Group

2010

  •  AHPRA (formerly Queensland Medical Board)
  • International Society of Experimental Hematology

2008

  • American Society of Hematology

2005

  • Haematology Society of Australia and New Zealand
  • Royal College of Pathologists of Australasia

2001

  • Royal Australasian College of Physician

1999-2010

  • Queensland Medical Board (now AHPRA)

Life Member:  Fulbright Alumni Association

 

AWARDS RECOGNITION

 

2019

  • Ralph Doherty QIMR Berghofer Prize for outstanding achievement and leadership in Medical research

2018

  • Metro North Research Awards: Discovery and Innovation – Highly Commended

2017-2021

  • CSL Centenary Fellowship ($1,250,000)

2017-2019

  • Associate Member of the Australian Academy of Health and Medical Sciences

2017

  • Cure Cancer Australia: Researcher of the Year

2016 

  • nominated, NHMRC Gottshalke Award
  • finalist, Queensland Health Metro North Research Excellence Awards
  • nominated, Metcalf Award, Australian Society for Stem Cell Research

2015

  • finalist, BUPA Emerging Researcher Award
  • Mercator Fellow, Otto Von-Guerike University Hospital, Magdeburg Germany

 2014-2016

  • National Health and Medical Research Council (NHMRC) Career Development Fellowship

2013

  • University of Queensland Dean’s Award for Research Higher Degree Excellence

 2011-2014

  • Leukaemia Foundation of Australia/Cure Cancer Foundation Postdoctoral Fellowship

2008

  • NHMRC Postgraduate Award

2007

  • Fulbright Postgraduate Scholarship, Alumni (WG Walker) Award for top ranked postgraduate scholarship
  • Haematology Society of Australia and New Zealand/ Novartis, Young Investigator Award
  • Royal College of Pathologists of Australasia Travel Grant

2006

  • Haematology Society of Australia and New Zealand, Queensland Branch Travel Award
  • Royal Australasian College of Physicians Advanced Trainee Research Award Queensland

1999

  • AMAQ memorial prize University of Queensland, Awarded for the top student in clinical medicine

 

EDUCATIONAL BACKGROUND

2012: PhD, University of Queensland School of Medicine

2008: Fellow Royal Australasian College of Physicians (Clinical Haematology)

2008: Fellow Royal College of Pathologists of Australasia (Haematopathology)

1999: Bachelor of Medicine, Bachelor of Surgery, Honours (Class II), University of Queensland